title: G-CSF mobilized vs conventional donor lymphocytes for therapy of relapse or incomplete engraftment after allogeneic hematopoietic transplantation.
abstract: There is little data comparing the activity and toxicity of donor lymphocyte therapy with granulocyte (G)-CSF-mobilized cells (G-donor lymphocyte infusion (DLI)) with the conventionally collected DLI (C-DLI) after allogeneic blood or marrow transplantation. We retrospectively evaluated 67 patients to compare the efficacy and toxicity of GCSF-mobilized DLI with C-DLI in the treatment of relapse of malignant disease or poor donor engraftment post transplant. We assessed clinical outcomes that may represent the immunological outcome of DLI. The median OS was 210 days (range 3-2436 days), 291 days (range 17-1491 days) in the G-DLI group (15 patients) and 207.5 days (range 3-2436 days) in the C-DLI group (52 patients). The median PFS time was 72 days (range 8-1491 days) in the G-DLI group vs 82 days (range 1-2436 days) in the C-DLI group. Rates of post DLI GVHD and improvement in donor engraftment were similar in the G-DLI and C-DLI groups. We conclude that G-DLI appears to have similar therapeutic activity to that seen with C-DLI, and where such cells are available they may be substituted for conventional donor lymphocytes.
authors.affiliation: Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA 17033, USA.
authors.forename: K K S
authors.initials: KK
authors.lastname: Abbi
authors.forename: J
authors.initials: J
authors.lastname: Zhu
authors.forename: W C
authors.initials: WC
authors.lastname: Ehmann
authors.forename: E
authors.initials: E
authors.lastname: Epner
authors.forename: M
authors.initials: M
authors.lastname: Carraher
authors.forename: J
authors.initials: J
authors.lastname: Mierski
authors.forename: G
authors.initials: G
authors.lastname: Talamo
authors.forename: K
authors.initials: K
authors.lastname: Lucas
authors.forename: W
authors.initials: W
authors.lastname: Rybka
authors.forename: D
authors.initials: D
authors.lastname: Claxton
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D006085:Graft Survival / Q000187:drug effects*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D017710:Lymphocyte Transfusion / Q000379:methods*; D008214:Lymphocytes / Q000166:cytology; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D014019:Tissue Donors; D014184:Transplantation, Homologous; D055815:Young Adult
chemical_list: D016179:Granulocyte Colony-Stimulating Factor